Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.

Singh, Satish K; Luisi, Donna L; Pak, Roger H

Singh, Satish K; Luisi, Donna L; Pak, Roger H.

Affiliation

Singh SK; Pfizer, Inc., Pharmaceutical R&D, 700 Chesterfield Parkway West, Chesterfield, Missouri, 63017, USA.
Luisi DL; Pfizer, Inc., Pharmaceutical R&D, 1 Burtt Road, Bldg. K, Andover, Massachusetts, 01810, USA.
Pak RH; Pfizer, Inc., Pharmaceutical R&D, 1 Burtt Road, Bldg. K, Andover, Massachusetts, 01810, USA. roger.pak@pfizer.com.

Pharm Res ; 32(11): 3541-71, 2015 Nov.

Article in En | MEDLINE | ID: mdl-25986175

Subject(s)

Antibodies, Monoclonal/chemistry; Drug Design; Immunoconjugates/chemistry; Pharmaceutical Preparations/chemistry; Animals; Antibodies, Monoclonal/administration & dosage; Antibodies, Monoclonal/pharmacokinetics; Antibody Affinity; Binding Sites, Antibody; Chemical Phenomena; Drug Stability; Glycosylation; Humans; Immunoconjugates/administration & dosage; Immunoconjugates/pharmacokinetics; Models, Molecular; Pharmaceutical Preparations/administration & dosage; Protein Engineering

Key words

antibody-drug conjugate; formulation; linker; payload; physicochemical characteristics

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Pharmaceutical Preparations / Drug Design / Immunoconjugates / Antibodies, Monoclonal Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Pharm Res Year: 2015 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google